Alumis Inc
Veridion Score
BETALOW CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ALMS moving today?
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ALMS overview
Related filings and maps
Congress activity in ALMS
No receipt-qualified Congressional disclosure is present for ALMS in the cached public ledger.
ALMS contract awards, year to date.
Public federal awards linked to this ticker.
ALMS lobbying filings, year to date.
Registered lobbying filings matched to Alumis Inc.